Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

BACKGROUND AND AIMS: The National Multiple Sclerosis Society and other expert organizations recommended that all patients with multiple sclerosis (MS) should be vaccinated against COVID-19. However, the effect of disease-modifying therapies (DMTs) on the efficacy to mount an appropriate immune respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Harari, Gil, Magalashvili, David, Sonis, Polina, Dolev, Mark, Menascu, Shay, Flechter, Shlomo, Falb, Rina, Gurevich, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072850/
https://www.ncbi.nlm.nih.gov/pubmed/34035836
http://dx.doi.org/10.1177/17562864211012835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072850/
https://www.ncbi.nlm.nih.gov/pubmed/34035836
http://dx.doi.org/10.1177/17562864211012835

Ejemplares similares